Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Does this type of immune system issue fit any of the work Sareum does?
https://www.bbc.co.uk/news/health-55022288
I hear what you are saying but for me a proactive RNS (rather than share chat from an informed poster on here) would be much more preferable than the usual silence from SAR. I've been invested in SAR for over a decade so I am well used to the radio silence. I just feel that my investment in SAR would be worth substantially more if they were better at their PR/comms. The more people that know about SAR's clever science the better. Here's to the next few months. I'm sure it will be a profitable period for us all.
Basil i beg to differ. I don't see how one of our resident experts finding something out on the web and sharing it here among 100 or 200 posters (more than half of those being the c0ckwombles who only arrive after an RNS) affects the SP prior to an RNS. Most of us are LTH, adding when we can as we already know what is coming.
If someone finds out Sierra are finally going to cough up the overdue milestone, then yes some of us will buy more. but what effect would that have on the SP? Very little. Maybe a 2%-5% rise before the actual RNS. (a rise that is already wiped out by the ridiculous spreads)
Few of us might buy another 500k, or 1m if we are fortunate enough to be in that position. The RNS goes to a much wider audience, and draws in the crowds, the money and the spikes in SP.
I agree we should be notified about the confirmation letter. I SAR have had the confirmation, why haven't they told us? If they haven't had the confirmation letter, why not. What is taking so long? Like I said. Be careful what you wish for. The market may not like the answer. Personally, I want Tim and John to gang bust the other preclinical work so they can announce it by the end of this year, preferably before the AGM. Covid really does become a side play at that point. The report released yesterday does a good job at pointing out the risks Sareum face and clearly, we are still on a knife-edge until we get news from our actual porfolio.
My concern is that one of our intrepid (& brilliant) researchers here will find out from UKRI. It will then be consequently posted on here first before being followed up by Sareum via RNS and the opportunity for a news event will have been missed. We've seen this a few times this year already where posts have appeared and then an RNS or tweet has followed and it doesn't really help our share price. Those bland tweets just act as a throw away rather than creating real investor interest via the official channels, which as we all know are digested by a wider group of investors (with all due respect to this share chat)
Hi Potnak - absolutely take your point that Covid is a sideshow and that cancer/immunotherapy will be the main value drivers. That said Tim has confirmed that Sareum is jumping on the Covid bandwagon and has been provisionally awarded a grant. It is wholly reasonable to expect a timely update as to the final sign off of the grant by UKRI and confirmation that work is underway.
We know what the plan is. Finish Preclinical work and possibly POC. 6 month timeline. I agree about the grant confirmation though. Be careful what you wish for. 100's of millions of people could be vaccinated by this time we finish pre-clinical. Still seems a lot here are here because of Covid play and that support will melt away as Covid goes on the back burner. I'm not here for Covid play. There is more long term value in Cancer and Immunutherapey.
I agree, I can only think they are trying to prevent a quick rise followed by a another fall if further vaccine news. Perhaps they are waiting for something more substantial.
Following the โWe are delighted that UKRI has indicated its conditional support for our programme to investigate the therapeutic potential of SDC-1801, our proprietary TYK2/JAK1 inhibitor, in severe phase COVID-19", I must admit that I was hoping for more news by now:
1. I was assuming that "A further announcement will be made in due course as and when appropriate", meant a follow up RNS once the "indication" became a formal grant. i.e. to keep the news flow momentum going on this news worthy topic to stimulate investor interest in Sareum. I'm presuming that 4 weeks on Sareum have now received more than an indication and that funds are in the bank or there is at least final documentation? The market should be be kept in the loop following the initial RNS.
2. What is the plan / are they partnering with another pharma on it etc.
Surely, they have learnt from our peers that the days of being coy with information relevant to share holders just holds the share price back?